Functional study of dextran-graft-poly((2-dimethyl amino)ethyl methacrylate) gene delivery vector for tumor therapy

Journal of Biomaterials Applications

Volumn 28, Issue 1, 2013, Pages 125-135

  Li, Wen Bin ^a   Yuan, Wei ^a   Xu, Fu Jian ^b   Zhao, Chen ^a   Ma, Jie ^a   Zhan, Qi Min ^a  

^a CANCER HOSPITAL   (China)

^b BEIJING UNIVERSITY OF CHEMICAL TECHNOLOGY   (China)

Author keywords

DPD; gene therapy; pEGFP C1 p53; tumor suppression

Indexed keywords

AGAROSE GEL ELECTROPHORESIS; DPD; GENE DELIVERY SYSTEMS; GENE DELIVERY VECTORS; GREEN FLUORESCENT PROTEIN; PEGFP-C1-P53; TRANSFECTION EFFICIENCY; TUMOR SUPPRESSION;

CELL DEATH; CELL PROLIFERATION; DEXTRAN; ELECTROPHORESIS; GENE THERAPY; GENE TRANSFER; GRAFTING (CHEMICAL); LIPOSOMES; PARTICLE SIZE; ZETA POTENTIAL;

TUMORS;

DEXTRAN; ENHANCED GREEN FLUORESCENT PROTEIN; LIPOFECTAMINE; POLY[(2 DIMETHYLAMINO)METHACRYLIC ACID ETHYL ESTER]; POLYMER; PROTEIN P53; UNCLASSIFIED DRUG;

AGAR GEL ELECTROPHORESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CELL CYCLE ARREST; CELL CYCLE PHASE; CELL STRAIN MCF 7; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO GENE TRANSFER; IN VIVO STUDY; LIPOSOMAL GENE DELIVERY SYSTEM; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PARTICLE SIZE; PLASMID; SYNTHESIS; TOXICITY TESTING; TUMOR CELL; TUMOR MODEL; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; WESTERN BLOTTING; WILD TYPE; ZETA POTENTIAL;

DPD; GENE THERAPY; PEGFP-C1-P53; TUMOR SUPPRESSION;

ANIMALS; APOPTOSIS; BIOCOMPATIBLE MATERIALS; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; DEXTRANS; FEMALE; GENE TRANSFER TECHNIQUES; GENES, P53; GENETIC THERAPY; GENETIC VECTORS; HUMANS; LIPIDS; MATERIALS TESTING; MCF-7 CELLS; METHACRYLATES; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; NYLONS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84879757185     PISSN: 08853282     EISSN: 15308022     Source Type: Journal    
DOI: 10.1177/0885328212440345     Document Type: Article

References (40)

1. Hunt KK, Vorburger SA. Gene therapy. Hurdles and hopes for cancer treatment. Science. 2002 ; 297: 415-416
2. Somia N, Verma IM. Gene therapy: trials and tribulations. Nat Rev Genet. 2000 ; 1: 91-99
3. Kaplitt MG, Feigin A, Tang C, et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet. 2007 ; 369: 2097-2105
4. Yang ZR, Wang HF, Zhao J, et al. Recent developments in the use of adenovirus and immunotoxins in cancer gene therapy. Cancer gene Ther. 2007 ; 14: 599-615
5. Mintzer MA, Simanek EE. Nonviral vectors for gene delivery. Chem Rev. 2009 ; 109: 259-302
6. DonKuru M, Badea L, Wettig S, et al. Advancing nonviral gene delivery: lipid- and surfactant-based nanoparticle design strategies. Nanomedicine (Lond). 2010 ; 5: 1103-1127
7. Zhang S, Zhao Y, Zhao B, et al. Hybrids of nonviral vectors for gene delivery. Bioconjug Chem. 2010 ; 21: 1003-1009
8. Yu H, Wagner E. Bioresponsive polymers for nonviral gene delivery. Curr Opin Mol Ther. 2009 ; 11: 165-178
9. Kawakami S, Higuchi Y, Hashida M. Nonviral approaches for targeted delivery of plasmid DNA and oligonucleotide. J Pharm Sci. 2008 ; 97: 726-745
10. St George JA. Gene therapy progress and prospects: adenoviral vectors. Gene Ther. 2003 ; 10: 1135-1141
11. Pack DW, Hoffman AS, Pun S, et al. Design and development of polymers for gene delivery. Nat Rev Drug Discov. 2005 ; 4: 581-593
12. Al-Dosari MS, Gao X. Nonviral gene delivery: principle, limitations, and recent progress. AAPS J. 2009 ; 11: 671-681
13. Seow Y, Wood MJ. Biological gene delivery vehicles: beyond viral vectors. Mol Ther. 2009 ; 17: 767-777
14. Montier T, Benvegnu T, Jaffres PA, et al. Progress in cationic lipid-mediated gene transfection: a series of bio-inspired lipids as an example. Curr Gene Ther. 2008 ; 8: 296-312
15. Felgner PL, Tsai YJ, Sukhu L, et al. Improved cationic lipid formulations for in vivo gene therapy. Ann N Y Acad Sci. 1995 ; 772: 126-139
16. Yamano S, Dai J, Moursi AM. Comparison of transfection efficiency of nonviral gene transfer reagents. Mol Biotechnol. 2010 ; 46: 287-300
17. Eliyahu H, Makovitzki A, Azzam T, et al. Novel dextran-spermine conjugates as transfecting agents: comparing water-soluble and micellar polymers. Gene Ther. 2005 ; 12: 494-503
18. Azzam T, Eliyahu H, Shapira T, et al. Polysaccharide-oligoamine based conjugates for gene delivery. J Med Chem. 2002 ; 45: 1817-1824
19. Yudovin-Farber I, Yanay C, Azzam T, et al. Quaternary ammonium polysaccharides for gene delivery. Bioconjug Chem. 2005 ; 16: 1196-1203
20. Wang ZH, Li WB, Ma J, et al. Functionalized nonionic dextran backbones by atom transfer radical polymerization for efficient gene delivery. Macromoleculars. 2011 ; 44: 230-239
21. Green DR, Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature. 2009 ; 458: 1127-1130
22. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell. 2009 ; 137: 413-431
23. Zuckerman V, Wolyniec K, Sionov RV, et al. Tumour suppression by p53: the importance of apoptosis and cellular senescence. J Pathol. 2009 ; 219: 3-15
24. Choi SH, Jin SE, Lee MK, et al. Novel cationic solid lipid nanoparticles enhanced p53 gene transfer to lung cancer cells. Eur J Pharm Biopharm. 2008 ; 68: 545-554
25. Lu Q, Teng GJ, Zhang Y, et al. Enhancement of p53 gene transfer efficiency in hepatic tumor mediated by transferrin receptor through trans-arterial delivery. Cancer Biol Ther. 2008 ; 7: 218-224
26. Palacios G, Crawford HC, Vaseva A, et al. Mitochondrially targeted wild-type p53 induces apoptosis in a solid human tumor xenograft model. Cell Cycle. 2008 ; 7: 2584-2590
27. Bisht HS, Soundara Manickam D, Oupicky YD. Temperature-controlled properties of DNA complexes with poly(ethylenimine)-graft-poly(N- isopropylacrylamide). Biomacromolecules. 2006 ; 7: 1169-1178
28. Xu FJ, Li HZ, Li J, et al. Pentablock copolymers of poly(ethylene glycol), poly((2-dimethyl amino)ethyl methacrylate) and poly(2-hydroxyethyl methacrylate) from consecutive atom transfer radical polymerizations for non-viral gene delivery. Biomaterials. 2008 ; 29: 3023-3033
29. Ganapathy-Kanniappan S, Geschwind JF, Kunjithapatham R, et al. The pyruvic acid analog 3-bromopyruvate interferes with the tetrazolium reagent MTS in the evaluation of cytotoxicity. Assay Drug Dev Technol. 2010 ; 8: 258-262
30. Romano G. Current development of nonviral-mediated gene transfer. Drug News Perspect. 2007 ; 20: 227-231
31. Qian Y, Chen X. Tumor suppression by p53: making cells senescent. Histol Histopathol. 2010 ; 25: 515-526
32. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001 ; 411: 342-348
33. Speris CK, Hwang M, Kim S, et al. Harnessing the cell death pathway for targeted cancer treatment. Am J Cancer Res. 2011 ; 1: 43-61
34. LeBlanc H, Lawrence D, Varfolomeev E, et al. Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med. 2002 ; 8: 274-281
35. Ventura A, Kirsch DG, McLaughlin ME, et al. Restoration of p53 function leads to tumour regression in vivo. Nature. 2007 ; 445: 661-665
36. Kreis NN, Sanhaji M, Kramer A, et al. Restoration of the tumor suppressor p53 by downregulating cyclin B1 in human papillomavirus 16/18-infected cancer cells. Oncogene. 2010 ; 29: 5591-5603
37. Junttila MR, Karnezis AN, Garcia D, et al. Selective activation of p53-mediated tumor suppression in high-grade tumors. Nature. 2010 ; 468: 567-571
38. Wang H, Ma X, Ren S, et al. A small-molecule inhibitor of MDMX activates p53 and induces apoptosis. Mol Cancer Ther. 2011 ; 10: 69-79
39. Guo C, Liu K, Zheng Y, et al. Apoptosis induced by an antagonist peptide against HPV16 E7 in vitro and in vivo via restoration of p53. Apoptosis. 2011 ; 16: 606-618
40. Zhang G, Gurtu V, Kain SR, et al. Early detection of apoptosis using a fluorescent conjugate of annexin V. Biotechniques. 1997 ; 23: 525-531